Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA.
Annu Rev Med. 2010;61:153-67. doi: 10.1146/annurev.med.042508.093728.
Despite more than 25 years of concerted worldwide research, the development of a safe and effective HIV-1 vaccine remains elusive. Prototype antibody-based and T cell-based HIV-1 vaccines have failed to show efficacy in clinical trials to date. Next-generation HIV-1 vaccine candidates are in various stages of preclinical and clinical development, but key scientific obstacles pose major challenges for the field. Critical hurdles include the enormous global diversity of the virus and the challenges associated with generating broadly reactive neutralizing antibody and cellular immune responses. We review the current state of the HIV-1 vaccine field and outline strategies that are being explored to overcome these roadblocks.
尽管经过 25 年多的全球协同研究，安全有效的 HIV-1 疫苗的研发仍然难以实现。目前，基于抗体和 T 细胞的 HIV-1 疫苗原型在临床试验中未能显示出疗效。新一代 HIV-1 疫苗候选物处于临床前和临床开发的各个阶段，但关键的科学障碍给该领域带来了重大挑战。主要障碍包括病毒的巨大全球多样性以及产生广泛反应性中和抗体和细胞免疫反应的挑战。我们回顾了 HIV-1 疫苗领域的现状，并概述了正在探索的克服这些障碍的策略。
